NPAT was 3.85m based on 31.3m revenue which is not 57c profit per $1 revenue (thats gross margin)..Actual NPAT Margin is more like 12.3% of revenue
From page 14 of FY14 Preliminary Report and 13 of Fy 13 Preliminary report
Aust Revenue was up from 15M to 20M an increase of 33%
Asia Revenue was up from 3.1m to 4.5m an increase of 45%
Europe Revenue was up from 1.6m to 2.6m an increase of 62%
North America Revenue was up from 8.7m to 11.5m an increase of 32%
Based on this information above I think you could possibly conservatively say
FY15 Aus 23 Asia 5.5 Europe 3.3 Nth America 13.5 = 45.3m Rev = 5.57m Profit 6.2cps
FY16 Aus 26 Asia 6.5 Europe 4 Nth America 17 = 53.5m Rev = 6.58m Profit 7.4cps
Based on 89,000,000 shares
Means right now its on a PE of 23
FY15 PE of 7.5 (estimate only may not come true)
FY16 PE of 6.3 (estimate only may not come true)
If we assume that growth cant be sustained beyond two years so in FY 16 actual PE is approx 15 then my amateur estimated Share price would be possibly 95c
Please note this may contain errors and actual performance is no indication of future performance...but thats my coaster calculations
- Forums
- ASX - By Stock
- AZV
- Ann: 2014 Results announcement
Ann: 2014 Results announcement, page-31
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AZV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online